Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
52
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite

Yan Zhou1 The School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang;2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Genyan Zhang2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Feng Wang2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Jin Wang2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Yanwei Ding2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Xinyu Li2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Chongtie Shi2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Jiakui Li2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, China
,
Chengkon Shih2 Department of Project Management, Medicinal Chemistry, Pharmacology, Drug Metabolism, and Pharmacokinetics, Toxicology, Xuanzhu Pharma, Jinan, ChinaCorrespondence[email protected]
&
Song You1 The School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, ShenyangCorrespondence[email protected]
 show all
Pages 5077-5087 | Published online: 20 Oct 2017

References

  • PaoWHutchinsonKEChipping away at the lung cancer genomeNat Med201218334935122395697
  • Gomez-PinillosAFerrariACmTOR signaling pathway and mTOR inhibitors in cancer therapyHematol Oncol Clin North Am201226348350522520976
  • YuanTLCantleyLCPI3K pathway alterations in cancer: variations on a themeOncogene200827415497551018794884
  • van der BroekRMohanSEytanDFChenZvan WaesCThe PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapiesOral Dis201521781582524219320
  • EngelmanJALuoJCantleyLCThe evolution of phosphatidylinositol 3-kinase as regulators of growth and metabolismNat Rev Genet20067860661916847462
  • Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
  • KandothCMcLellanMDVandinFMutational landscape and significance across 12 major cancer typesNature2013502747133333924132290
  • YaoJCShahMHItoTEverolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med2011364651452321306238
  • JankuFWhelerJJWestinSNPI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsJ Clin Oncol201230877778222271473
  • NetlandIAFørdeHESleireLDactolisib (NVP-BEZ235) toxicity in murine brain tumour modelsBMC Cancer20161665727542970
  • WenPYOmuroAAhluwaliaMSPhase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade gliomaNeuro Oncol20151791275128326019185
  • DollySOWagnerAJBendellJCPhase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumorsClin Cancer Res201622122874288426787751
  • ChiaSGandhiSJoyAANovel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancerCurr Oncol2015221334825684987
  • WongMHXueABaxterRCPavlakisNSmithRCUpstream and downstream co-inhibition of mitogen-activated protein kinase and PI3K/Akt/mTOR pathways in pancreatic ductal adenocarcinomaNeoplasia201618742543527435925
  • SimioniCUltimoSMartelliAMSynergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human acute lymphoblastic leukemiaOncotarget2016748798427985327821800
  • WuFShuCTinventorsXuanzhu Pharma, assigneePI3K and/or mTOR inhibitorWorld Intellectual Property Organization patentWO20140403732013912
  • WuFZhangYinventorsXuanzhu Pharma, assigneeThree-ring PI3K and/or mTOR inhibitorWorld Intellectual Property Organization patentWO201307169820121116
  • WuFXueJJLiLinventorsXuanzhu Pharma, assigneePI3K and/or mTOR inhibitor prodrugWorld Intellectual Property Organization patentWO20141540262014328
  • RautioJKumpulainenHHeimbachTProdrugs: design and clinical applicationsNat Rev Drug Discov20087325527018219308
  • BrowneTRKuglerAREldonMAPharmacology and pharmacokinetics of fosphenytoinNeurology1996466 Suppl 1S3S78649612
  • StellaVJNti-AddaeKWProdrug strategies to overcome poor water solubilityAdv Drug Deliv Rev200759767769417628203
  • VariaSASchullerSSloanKBStellaVJPhenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral useJ Pharm Sci1984738106810736491911
  • OttPAAdamsSSmall-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatmentImmunotherapy20113221322721322760
  • AdamsJLSmothersJSrinivasanRHoosABig opportunities for small molecules in immuno-oncologyNat Rev Drug Discov201514960362226228631
  • RibasAButlerMLutzkyJPhase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanomaJ Clin Oncol20153315 Suppl 7S3003

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.